{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Anemia : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anemia : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blurred vision : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Blurred vision : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bruising : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Bruising : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"Chills : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Chills : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Diarrhea : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diarrhea : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Dizziness : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Dizziness : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Eye disorders - Other, specify : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Eye disorders - Other, specify : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Fatigue : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Fatigue : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Fever : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Fever : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Flu like symptoms : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Flu like symptoms : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Flushing : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Flushing : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"General disorders and administration : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"General disorders and administration: Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Headache : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Headache : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Heart failure : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Heart failure : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypotension : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hypotension : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Hypothyroidism : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Hypothyroidism : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Lymphocyte count decreased : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphocyte count decreased : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Myalgia : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Myalgia : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Nausea : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Nausea : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Neutrophil count decreased : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Neutrophil count decreased : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Pain : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Pain : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelet count decreased : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Platelet count decreased : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pleural effusion : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Pleural effusion : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Serum amylase increased : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Serum amylase increased : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Sinus bradycardia : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Sinus bradycardia : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Vomiting : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Vomiting : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Weight gain : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Weight gain : Grade 3-4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"White blood cell decreased : Grade 1-2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"White blood cell decreased : Grade 3-4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Number of participants with adverse events (by Grade) that were possibly, probably or definitely related to the combined study immunotherapy regimen (αDC1 vaccines + CKM) per CTCAE v 4.0 (Common Terminology Criteria for Adverse Events).","groups":[{"description":"α DC1 Vaccine\n\nand\n\nChemokine Modulatory Regimen:\n\nCelecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \\& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\\^2 or 20 MU/m\\^2 (T-Fri)","id":"OG000","title":"α DC1 Vaccine + 1 Cycle of Chemokine Modulatory Regimen"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for for completing surgery.","reportingStatus":"POSTED","timeFrame":"Up to 24 weeks","title":"Adverse Events Possibly, Probably or Definitely Related to Study Treatment","type":"PRIMARY","unitOfMeasure":"Participants"}